BioFocus DPI, IOWH sign €3 million deal
Register for free to listen to this article
Listen with Speechify
0:00
5:00
STORY UPDATE
SAN FRANCISCO—November 1, 2006—Just weeks after announcing the start of a large project to combat diarrheal diseases, the Institute for OneWorld Health announced the project had received a major infusion of cash from the Bill and Melinda Gates Foundation. The announcement of the $46-million grant was made at the Global Forum for Health Research's annual meeting Forum 10, held in Cairo.
MECHELEN, Belgium—Galapagos NV recently announced its services division BioFocus DPI has entered into a drug discovery collaboration with San Francisco-based non-profit drug company Institute for OneWorld Health (IOWH). The 2.5-year collaboration will focus on the discovery and development of new therapeutics targeting diarrheal diseases endemic to the developing world.
"Our desire was to make an impact on the two million deaths a year that occur due to diarrhea as a direct cause," explains Dr. Victoria Hale, CEO of IOWH, adding that diarrhea contributes to the deaths of another three to four million people. "It is an ultra-neglected disease that affects as many or more people as the big three—HIV, TB, and malaria—and yet there wasn't a lot of effort around it."
According to Hale, the two companies will be taking a very different approach to treating diarrheal diseases—for example, cholera and enterotoxigenic E. coli (ETEC)—by looking at disease pathology rather than the specific pathogens.
"We didn't want to develop an anti-infective because there are too many pathogens, so we decided to go at diarrhea in another way," she says. "We wanted to see if we could develop some products that would prevent or reduce dehydration."
To accomplish this, IOWH is coordinating the effort with a series of partners, including BioFocus DPI, to establish what amounts to a distributed company. UCSF professor Dr. Alan Verkman has developed a medium-throughput bioassay to monitor the impact of small-molecule candidates on the cystic fibrosis transmembrane receptor (CFTR), their anti-secretory target in the intestine.
For its part, BioFocus DPI will act as the medicinal chemistry division for the project. According to Onno van de Stolpe, Galapagos CEO, the project has been met with quite a bit of enthusiasm at BioFocus DPI and the team looks forward to finding appropriate solutions to the challenges ahead.
"The project further benefits BioFocus DPI by adding another major client to our customer base and supports our contention that the experience and technology base BioFocus DPI possesses can provide both innovative and cost-effective support to drug discovery projects—both for developed and developing world diseases," he says.
BioFocus DPI scientists will build lead candidates from a spectrum of molecules IOWH has been able to get from large pharmaceutical companies. "Because we're working in cholera and that truly is not a portfolio item, companies have been very willing to share their libraries with us from starting compounds, scaffolds upon which we can start our chemistry," Hale says.
Regarding the search for therapies for developing world diseases, Van de Stolpe recognizes there are some extra considerations in therapy design, including issues of cost of manufacture and distribution. But he also foresees challenges that will be the same as any other medicinal chemistry development project, such as balancing potency with side-effects and pharmacokinetic compliance.
